These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22268265)

  • 1. Evidence that the main adverse effect of ganirelix on pregnancy and implantation rates is on the embryo rather than the endometrium.
    Check JH; Cohen R; Amui J; Choe JK; Brasile D
    Clin Exp Obstet Gynecol; 2011; 38(4):326-7. PubMed ID: 22268265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of pregnancy rates following fresh and frozen embryo transfer according to the use of leuprolide acetate vs ganirelix vs cetrorelix.
    Check JH; Wilson C; Choe JK; Amui J; Katsoff B
    Clin Exp Obstet Gynecol; 2010; 37(2):105-7. PubMed ID: 21077496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frozen-thawed cleavage-stage embryo transfer cycles after previous GnRH agonist or antagonist stimulation.
    Bahçeci M; Ulug U; Erden HF; Tosun S; Ciray N
    Reprod Biomed Online; 2009 Jan; 18(1):67-72. PubMed ID: 19146771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
    Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
    J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated doses of GnRH antagonist at midcycle in artificial frozen embryo transfer cycles may not affect pregnancy outcomes.
    Palmerola KL; Hsu JY; Grossman LC; Sauer MV; Lobo RA
    Gynecol Endocrinol; 2017 Apr; 33(4):301-305. PubMed ID: 28010150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization.
    Posada MN; Vlahos NP; Jurema MW; Bracero NJ; Wallach EE; Garcia JE
    Fertil Steril; 2003 Jul; 80(1):103-10. PubMed ID: 12849810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation.
    Eldar-Geva T; Zylber-Haran E; Babayof R; Halevy-Shalem T; Ben-Chetrit A; Tsafrir A; Varshaver I; Brooks B; Margalioth EJ
    Reprod Biomed Online; 2007 Feb; 14(2):148-54. PubMed ID: 17298715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of GnRH agonists and antagonists in an ovular donation program].
    Saucedo de la Llata E; Moraga Sánchez MR; Batiza Reséndiz V; Santos Haliscak R; Galache Vega P; Hernández Ayup S
    Ginecol Obstet Mex; 2004 Feb; 72():53-6. PubMed ID: 15216901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antagonists vs agonists on in vitro fertilization outcome.
    Check ML; Check JH; Choel JK; Davies E; Kiefer D
    Clin Exp Obstet Gynecol; 2004; 31(4):257-9. PubMed ID: 15672958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study to determine the efficacy of controlled ovarian hyperstimulation regimen using a gonadotropin releasing hormone agonist versus antagonist in women of advanced reproductive age with varying degrees of oocyte reserve on outcome following in vitro fertilization-embryo transfer.
    Check JH; Choe JK; Cohen R; Wilson C
    Clin Exp Obstet Gynecol; 2013; 40(2):191-2. PubMed ID: 23971234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.
    Kol S; Lightman A; Hillensjo T; Devroey P; Fauser B; Tarlatzis B; Mannaerts B; Itskovitz-Eldor J
    Hum Reprod; 1999 Sep; 14(9):2242-4. PubMed ID: 10469687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF.
    Fasouliotis SJ; Laufer N; Sabbagh-Ehrlich S; Lewin A; Hurwitz A; Simon A
    J Assist Reprod Genet; 2003 Nov; 20(11):455-60. PubMed ID: 14714824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
    Gustofson RL; Larsen FW; Bush MR; Segars JH
    Fertil Steril; 2006 Jan; 85(1):251-4. PubMed ID: 16412770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.